The oxidative modification hypothesis of atherosclerosis: Does it hold for humans?

被引:342
作者
Witztum, JL
Steinberg, D
机构
[1] Univ Calif San Diego, Sch Med, Dept Med 0682, Div Endocrinol & Metab, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Sch Med, Specialized Ctr Res Mol Med & Atherosclerosis, La Jolla, CA 92093 USA
关键词
D O I
10.1016/S1050-1738(01)00111-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review suggests that oxidation of LDL is an important, if not obligatory, event in atherogenesis. The important clinical corollary is that inhibition of oxidation can inhibit atherosclerosis independent of lowering plasma cholesterol levels. This article surveys the extensive data supporting the presence of oxidized LDL in vivo in animal models; the many studies demonstrating that inhibition of oxidation by pharmacologic and/or genetic manipulations retards atherogenesis; the data in humans that supports a role for oxidation of LDL; and the results of intervention trials with antioxidant vitamins. Limitations of these trials that may have led to inconclusive results to date are discussed, and what this may mean for the oxidation hypothesis. The oxidation hypothesis is still viable, but a great deal needs to be learned in order to design the appropriate clinical trials to properly test the importance of oxidation in the pathogenesis of atherosclerosis in humans. (C) 2001, Elsevier Science Inc.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 103 条
  • [1] Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
  • [2] ENHANCED LEVELS OF LIPOPEROXIDES IN LOW-DENSITY-LIPOPROTEIN INCUBATED WITH MURINE FIBROBLASTS EXPRESSING HIGH-LEVELS OF HUMAN 15-LIPOXYGENASE
    BENZ, DJ
    MOL, M
    EZAKI, M
    MORIITO, N
    ZELAN, I
    MIYANOHARA, A
    FRIEDMANN, T
    PARTHASARATHY, S
    STEINBERG, D
    WITZTUM, JL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (10) : 5191 - 5197
  • [3] Bird DA, 1998, J LIPID RES, V39, P1079
  • [4] Removal of cholesterol from extrahepatic sources by oxidative mechanisms
    Björkhem, I
    Diczfalusy, U
    Lütjohann, D
    [J]. CURRENT OPINION IN LIPIDOLOGY, 1999, 10 (02) : 161 - 165
  • [5] THE ANTIOXIDANT BUTYLATED HYDROXYTOLUENE PROTECTS AGAINST ATHEROSCLEROSIS
    BJORKHEM, I
    HENRIKSSONFREYSCHUSS, A
    BREUER, O
    DICZFALUSY, U
    BERGLUND, L
    HENRIKSSON, P
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (01): : 15 - 22
  • [6] Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
    Boaz, M
    Smetana, S
    Weinstein, T
    Matas, Z
    Gafter, U
    Iaina, A
    Knecht, A
    Weissgarten, Y
    Brunner, D
    Fainaru, M
    Green, MS
    [J]. LANCET, 2000, 356 (9237) : 1213 - 1218
  • [7] Boaz M, 2001, CLIN NEPHROL, V55, P93
  • [8] A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit
    Bocan, TMA
    Rosebury, WS
    Mueller, SB
    Kuchera, S
    Welch, K
    Daugherty, A
    Cornicelli, JA
    [J]. ATHEROSCLEROSIS, 1998, 136 (02) : 203 - 216
  • [9] An animal model to study local oxidation of LDL and its biological effects in the arterial wall
    Calara, F
    Dimayuga, P
    Niemann, A
    Thyberg, J
    Diczfalusy, U
    Witztum, JL
    Palinski, W
    Shah, PK
    Cercek, B
    Nilsson, J
    Regnström, J
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (06) : 884 - 893